AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3190800 — intervention group
Group type: EXPERIMENTAL
Intervention: MDP-Lys(L18) every other day for 5 days
Number of subjects: 102
Study 3190800 — intervention group
Group type: EXPERIMENTAL
Intervention: MDP-Lys(L18) in patients with solid tumors
Number of subjects: 102
Study 3190800 — intervention group
Group type: EXPERIMENTAL
Intervention: MDP-Lys(L18) overall
Number of subjects: 102
Study 31738115 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia plus 200 IU onabotulinum toxin A
Number of subjects: 64
Study 31738115 — intervention group
Group type: COMPARATOR
Intervention: Local anesthesia alone
Number of subjects: 64
Study 31738115 — intervention group
Group type: EXPERIMENTAL
Intervention: Open label trial with onabotulinum toxin A
Number of subjects: 64
Study 30811457 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeons (both male and female)
Number of subjects: 415
Study 30811457 — intervention group
Group type: EXPERIMENTAL
Intervention: Female surgeons
Number of subjects: 415
Study 30811457 — intervention group
Group type: EXPERIMENTAL
Intervention: Male surgeons
Number of subjects: 415
Study 28264720 — intervention group
Group type: EXPERIMENTAL
Intervention: Fidelity oriented learning collaborative
Number of subjects: 32
Study 28264720 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous quality improvement-oriented learning collaborative
Number of subjects: 32
Study 26386786 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (1.0 mg twice daily)
Number of subjects: 302
Study 26386786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study 26386786 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline and Placebo
Number of subjects: 302
Study 23415877 — intervention group
Group type: COMPARATOR
Intervention: Anodal HD-tDCS
Number of subjects: 18
Study 23415877 — intervention group
Group type: COMPARATOR
Intervention: Cathodal HD-tDCS
Number of subjects: 18
Study 23415877 — intervention group
Group type: COMPARATOR
Intervention: Sham HD-tDCS
Number of subjects: 18
Study 17211114 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise program (60% to 80% intensity of maximal heart rate for 25 minutes, 3 times per week, for 6 weeks)
Number of subjects: 26
Study 17211114 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise treatment during the research period)
Number of subjects: 26
Study 12899796 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper ion electrochemistry (CIE) for bleeding due to hemorrhoid
Number of subjects: 202
Study 12899796 — intervention group
Group type: COMPARATOR
Intervention: Suppository treatment for bleeding due to hemorrhoid
Number of subjects: 202
Study 12899796 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper ion electrochemistry (CIE) for prolapse of hemorrhoid
Number of subjects: 202
Study 12899796 — intervention group
Group type: COMPARATOR
Intervention: Suppository treatment for prolapse of hemorrhoid
Number of subjects: 202
Study 12899796 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper ion electrochemistry (CIE)
Number of subjects: 202
Study 12899796 — intervention group
Group type: COMPARATOR
Intervention: Control side (routine hemostasis)
Number of subjects: 202
Study 10810687 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable suture anchors
Number of subjects: 18
Study 10810687 — intervention group
Group type: COMPARATOR
Intervention: Control shoulders
Number of subjects: 18
Study 10810687 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study 8800890 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral microwave thermotherapy (TUMT)
Number of subjects: 93
Study 8800890 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 93
Study 1310497 — intervention group
Group type: EXPERIMENTAL
Intervention: etanidazole (ETA) unmodified (2 g/m2, 3 times weekly for 17 doses)
Number of subjects: 54
Study 1310497 — intervention group
Group type: EXPERIMENTAL
Intervention: etanidazole (ETA) schedule adjustment
Number of subjects: 54
Study 1310497 — intervention group
Group type: EXPERIMENTAL
Intervention: etanidazole (ETA) individualized dose modification
Number of subjects: 54
Study 6704011 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasolacrimal occlusion (NLO)
Number of subjects: 0
Study 6704011 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyelid closure
Number of subjects: 0
Study 6704011 — intervention group
Group type: COMPARATOR
Intervention: No procedures (control)
Number of subjects: 0
Study 30484720 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave ablation (MWA)
Number of subjects: 66
Study 30484720 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional clamp‐crushing method)
Number of subjects: 66
Study 29018084 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral morphine (0.5 mg/kg)
Number of subjects: 154
Study 29018084 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (10 mg/kg)
Number of subjects: 154
Study 25858633 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) training program
Number of subjects: 154
Study 25858633 — intervention group
Group type: COMPARATOR
Intervention: Advice approach (Control group)
Number of subjects: 154
Study 23992206 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-invasive technique (Group B)
Number of subjects: 170
Study 23992206 — intervention group
Group type: COMPARATOR
Intervention: Standard laparoscopic myomectomy (Group A)
Number of subjects: 170
Study 20940337 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous insulin (5 U)
Number of subjects: 16
Study 20940337 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous insulin (10 U)
Number of subjects: 16
Study 20940337 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled Technosphere insulin (25, 50, and 100 U)
Number of subjects: 16
Study 19471136 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms and social support
Number of subjects: 695
Study 19471136 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical and functional characteristics of disease status
Number of subjects: 695
Study 19471136 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical and functional characteristics
Number of subjects: 695
Study 17344588 — intervention group
Group type: EXPERIMENTAL
Intervention: FK506 (tacrolimus) group, n=43
Number of subjects: 73
Study 15118650 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal zinc supplementation (25 mg zinc)
Number of subjects: 242
Study 15118650 — intervention group
Group type: COMPARATOR
Intervention: Prenatal supplementation without zinc (control group)
Number of subjects: 242
Study 11913306 — intervention group
Group type: EXPERIMENTAL
Intervention: Baking Soda Gum (AHDC)
Number of subjects: 48
Study 11913306 — intervention group
Group type: COMPARATOR
Intervention: Non-baking soda placebo gum
Number of subjects: 48
Study 9559732 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpreserved ketorolac tromethamine 0.5%
Number of subjects: 0
Study 9559732 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 0
Study 7884791 — intervention group
Group type: EXPERIMENTAL
Intervention: Moexipril monotherapy (7.5, 15, or 30 mg once daily)
Number of subjects: 281
Study 7884791 — intervention group
Group type: EXPERIMENTAL
Intervention: Moexipril combined with hydrochlorothiazide (15-30 mg daily with 12.5 mg hydrochlorothiazide)
Number of subjects: 281
Study 7884791 — intervention group
Group type: EXPERIMENTAL
Intervention: Moexipril monotherapy
Number of subjects: 281
Study 7884791 — intervention group
Group type: EXPERIMENTAL
Intervention: Moexipril combined with hydrochlorothiazide
Number of subjects: 281
Study 7884791 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse side effects of moexipril
Number of subjects: 281
Study 2905253 — intervention group
Group type: EXPERIMENTAL
Intervention: roxatidine acetate 150 mg
Number of subjects: 12
Study 2905253 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 30706520 — intervention group
Group type: EXPERIMENTAL
Intervention: Active strategy for the diagnosis and anticoagulant treatment of pulmonary embolism (PE)
Number of subjects: 746
Study 30706520 — intervention group
Group type: COMPARATOR
Intervention: Usual care (standard care without any diagnostic test for diagnosing PE)
Number of subjects: 746
Study 30706520 — intervention group
Group type: EXPERIMENTAL
Intervention: Active strategy for the diagnosis and anticoagulant treatment of PE
Number of subjects: 746
Study 28260202 — intervention group
Group type: EXPERIMENTAL
Intervention: High hypoxia (HH: FiO2 = 0.13)
Number of subjects: 12
Study 28260202 — intervention group
Group type: COMPARATOR
Intervention: Normoxia (NORM: FiO2 = 0.21)
Number of subjects: 12
Study 28260202 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypoxia (MH: FiO2 = 0.16)
Number of subjects: 12
Study 26378492 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity guideline attainment at 6 weeks posthospitalization
Number of subjects: 136
Study 26378492 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity guideline attainment at 4 months
Number of subjects: 136
Study 26378492 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity guideline attainment at 12 months
Number of subjects: 136
Study 26378492 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking behavior
Number of subjects: 136
Study 26378492 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity PA
Number of subjects: 136
Study 26378492 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous-intensity PA
Number of subjects: 136
Study 23210470 — intervention group
Group type: EXPERIMENTAL
Intervention: Acu‐TENS (application of TENS on BL13, Feishu)
Number of subjects: 18
Study 23210470 — intervention group
Group type: COMPARATOR
Intervention: Placebo‐TENS (similar to Acu‐TENS but without electrical output)
Number of subjects: 18
Study 23210470 — intervention group
Group type: EXPERIMENTAL
Intervention: Acu‐TENS
Number of subjects: 18
Study 21596605 — intervention group
Group type: EXPERIMENTAL
Intervention: Allostatic load score
Number of subjects: 0
Study 21596605 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure
Number of subjects: 0
Study 21596605 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure
Number of subjects: 0
Study 21596605 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA(1c)
Number of subjects: 0
Study 18000659 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib with ketoconazole (CYP3A4 inhibitor)
Number of subjects: 0
Study 18000659 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib
Number of subjects: 0
Study 17010056 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective estrogen receptor modifiers (tamoxifen, raloxifene)
Number of subjects: 0
Study 17010056 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors
Number of subjects: 0
Study 17010056 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 14634811 — intervention group
Group type: EXPERIMENTAL
Intervention: Mapping up with right and down with left
Number of subjects: 0
Study 14634811 — intervention group
Group type: COMPARATOR
Intervention: Stimulus-set position manipulation
Number of subjects: 0
Study 11128246 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin monotherapy after discontinuation of carbamazepine (CBZ)
Number of subjects: 275
Study 11128246 — intervention group
Group type: COMPARATOR
Intervention: Other antiepileptic medications
Number of subjects: 275
Study 11128246 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of carbamazepine (CBZ)
Number of subjects: 275
Study 9094871 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sucrose diet
Number of subjects: 42
Study 9094871 — intervention group
Group type: COMPARATOR
Intervention: Low-sucrose diet
Number of subjects: 42
Study 1493661 — intervention group
Group type: EXPERIMENTAL
Intervention: Propionyl-L-carnitine (PLC) 1 g b.i.d
Number of subjects: 50
Study 1493661 — intervention group
Group type: EXPERIMENTAL
Intervention: Propionyl-L-carnitine (PLC)
Number of subjects: 50
Study 1493661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 2859304 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapidly eliminated hypnotics (triazolam, midazolam, lormetazepam)
Number of subjects: 0
Study 2859304 — intervention group
Group type: EXPERIMENTAL
Intervention: Slowly eliminated hypnotics (flurazepam, quazepam)
Number of subjects: 0
Study 2859304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31345078 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonenhanced multidetector computed tomography (MDCT)
Number of subjects: 20
Study 31345078 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 subjects)
Number of subjects: 20
Study 31345078 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular stent placement (ESP)
Number of subjects: 20
Study 29490310 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondiabetic patients with peri-implantitis
Number of subjects: 171
Study 29490310 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients with peri-implantitis
Number of subjects: 171
Study 29490310 — intervention group
Group type: COMPARATOR
Intervention: Nondiabetic patients without peri-implantitis
Number of subjects: 171
Study 29490310 — intervention group
Group type: COMPARATOR
Intervention: Diabetic patients without peri-implantitis
Number of subjects: 171
Study 28327683 — intervention group
Group type: EXPERIMENTAL
Intervention: Oblique incision
Number of subjects: 146
Study 28327683 — intervention group
Group type: COMPARATOR
Intervention: Vertical incision
Number of subjects: 146
Study 28327683 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 146
Study 24472084 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound betamethasone 7 mg intramuscular injection (i.m.) once
Number of subjects: 60
Study 24472084 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium 75 mg twice a day for 7 days
Number of subjects: 60
Study 22995882 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 88
Study 22995882 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 88
Study 19962735 — intervention group
Group type: EXPERIMENTAL
Intervention: AlloDerm closure
Number of subjects: 20
Study 19962735 — intervention group
Group type: COMPARATOR
Intervention: Primary closure
Number of subjects: 20
Study 17907112 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-insulin-potassium (GIK) infusion
Number of subjects: 25
Study 17907112 — intervention group
Group type: COMPARATOR
Intervention: No GIK infusion (Control)
Number of subjects: 25
Study 16214489 — intervention group
Group type: EXPERIMENTAL
Intervention: Patella alta
Number of subjects: 27
Study 16214489 — intervention group
Group type: COMPARATOR
Intervention: Normal patellar position
Number of subjects: 27
Study 12405236 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention program
Number of subjects: 60
Study 12405236 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 60
Study 10486787 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 1157
Study 10486787 — intervention group
Group type: COMPARATOR
Intervention: HRT
Number of subjects: 1157
Study 10486787 — intervention group
Group type: COMPARATOR
Intervention: Estrogen
Number of subjects: 1157
Study 10486787 — intervention group
Group type: COMPARATOR
Intervention: Unopposed Estrogen
Number of subjects: 1157
Study 8609825 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbohydrate (CHO) drink without prior CHO-loading (NLC)
Number of subjects: 16
Study 8609825 — intervention group
Group type: COMPARATOR
Intervention: Water placebo after CHO-loading (CLP)
Number of subjects: 16
Study 2025478 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 10 mg i.v. followed by an infusion of 0.075 mg kg‐1 h‐1
Number of subjects: 17
Study 2025478 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 6894644 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyographic feedback during 20 minutes of isometric exercises
Number of subjects: 26
Study 6894644 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy (20 minutes of isometric exercises)
Number of subjects: 26
Study 6894644 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyographic feedback
Number of subjects: 26
Study 6894644 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 26
Study 6894644 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple regression analysis
Number of subjects: 26
Study 30257898 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftaroline disk diffusion with 30-μg disks
Number of subjects: 158
Study 30257898 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftaroline MIC of 2 μg/ml
Number of subjects: 158
Study 30257898 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftaroline MIC of 1 μg/ml
Number of subjects: 158
Study 30257898 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftaroline MIC of ≥4 μg/ml
Number of subjects: 158
Study 28887690 — intervention group
Group type: EXPERIMENTAL
Intervention: ACD (anterior cervical discectomy without fusion)
Number of subjects: 142
Study 28887690 — intervention group
Group type: EXPERIMENTAL
Intervention: ACDF (anterior cervical discectomy with fusion by stand-alone cage)
Number of subjects: 142
Study 28887690 — intervention group
Group type: EXPERIMENTAL
Intervention: ACDA (anterior cervical discectomy with arthroplasty)
Number of subjects: 142
Study 28887690 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 142
Study 25729196 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal decompression therapy (SDTG, n=15)
Number of subjects: 30
Study 25729196 — intervention group
Group type: EXPERIMENTAL
Intervention: General traction therapy (GTTG, n=15)
Number of subjects: 30
Study 23187955 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic yoghurt (200g per day for 9 weeks)
Number of subjects: 70
Study 23187955 — intervention group
Group type: COMPARATOR
Intervention: Conventional yoghurt (200g per day for 9 weeks)
Number of subjects: 70
Study 21456017 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib monotherapy
Number of subjects: 138
Study 18679072 — intervention group
Group type: COMPARATOR
Intervention: PEG‐IFN monotherapy (n=64)
Number of subjects: 210
Study 18679072 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN + RBV (n=57)
Number of subjects: 210
Study 18679072 — intervention group
Group type: COMPARATOR
Intervention: PEG‐IFN + RBV (n=42)
Number of subjects: 210
Study 18679072 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN + RBV + amantadine (n=47)
Number of subjects: 210
Study 16531440 — intervention group
Group type: EXPERIMENTAL
Intervention: tranexamic acid 10 mg kg(‐1) i.v. just before tourniquet deflation and 3 h later
Number of subjects: 127
Study 16531440 — intervention group
Group type: EXPERIMENTAL
Intervention: epsilon‐aminocaproic acid 100 mg kg(‐1) before tourniquet deflation followed by continuous perfusion (1 g h(‐1)) during 3 h
Number of subjects: 127
Study 16531440 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 127
Study 16531440 — intervention group
Group type: EXPERIMENTAL
Intervention: tranexamic acid and epsilon‐aminocaproic acid
Number of subjects: 127
Study 11966791 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir 500 mg twice a day for 10 days
Number of subjects: 120
Study 11966791 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir 500 mg twice a day for 14 days
Number of subjects: 120
Study 9617328 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT with OK-432
Number of subjects: 0
Study 9617328 — intervention group
Group type: COMPARATOR
Intervention: UFT
Number of subjects: 0
Study 7593775 — intervention group
Group type: EXPERIMENTAL
Intervention: Polarized light photography
Number of subjects: 0
Study 7593775 — intervention group
Group type: EXPERIMENTAL
Intervention: Polarized light photography with precise framing and mapping
Number of subjects: 0
Study 2469654 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 200/0.5 10%
Number of subjects: 0
Study 2469654 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran 40 10%
Number of subjects: 0
Study 2469654 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrolyte solution
Number of subjects: 0
Study 162923 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenine arabinoside (20 mg/kg of body weight, intravenously every 24 hr for seven days in an 8-hr infusion)
Number of subjects: 20
Study 162923 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 20
Study 162923 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenine arabinoside
Number of subjects: 20
Study 7362724 — intervention group
Group type: EXPERIMENTAL
Intervention: Suxamethonium 1.0 mg kg‐1
Number of subjects: 2
Study 7362724 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone, pancuronium bromide
Number of subjects: 2
Study 30694011 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 116
Study 30694011 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference (WC)
Number of subjects: 116
Study 29044764 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (systolic BP target of <120 mmHg)
Number of subjects: 9361
Study 29044764 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (systolic BP target of <140 mmHg)
Number of subjects: 9361
Study 26867157 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab added to docetaxel-based chemotherapy
Number of subjects: 77
Study 26867157 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel-based chemotherapy alone
Number of subjects: 77
Study 25116230 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental formula (EF) with added milk fat globule membrane (MFGM)
Number of subjects: 240
Study 25116230 — intervention group
Group type: COMPARATOR
Intervention: Standard formula (SF)
Number of subjects: 240
Study 25116230 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-fed reference (BFR)
Number of subjects: 240
Study 21936758 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-centred practice (FCP)
Number of subjects: 20
Study 21936758 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (UP)
Number of subjects: 20